14種抗癌藥價格下調 9月起患者或可買到

China's state medical insurance administration has lowered the procurement prices of 14 cancer drugs, asking provincial-level drug procurement platforms to follow the new standard by the end of September.

中國國家醫療保障管理部門近日降低了14種抗癌藥品的採購價格，並要求省級藥品採購平臺在9月底前遵循新標準。

The National Healthcare Security Administration said last Saturday patients are expected to be able to buy these drugs starting from September.

國家醫療保障局上週六表示，預計從九月起，患者就可以買到這些藥物了。

The decision was based on a recent circular on the adjustment of medical insurance reimbursement and procurement prices of cancer drugs.

這項決定的提出是基於最近發佈的關於調整醫保對抗癌藥的免除比例和採購價格的通告。

The administration will further its guidance to make sure the new prices are implemented, in order to allow the public to enjoy the benefits as soon as possible, a source from the administration said.

據來自該機構的的消息人士透露，爲使大衆儘快享受到這項利益，他們將做進一步工作，以確保新的定價可以得以實施。

Negotiations have been underway between the administration and pharmaceutical companies to add more affordable cancer drugs to the country's medical insurance reimbursement list.

管理機構和製藥企業之間的協商仍在進行中，從而將更多的人們可負擔起的抗癌藥物加入到醫療保險補償目錄之中。

A range of drugs have been selected, with the administration confirming the producers' willingness to further negotiate. The drugs are all crucial in dealing with hematological neoplasms and solid tumors, and have great clinical value and bode huge benefits to patients, the administration said.

目前一些藥品已選定，正在確認藥企是否有進一步協商的意願。管理機構表示，這些藥物對治療血液腫瘤和實體固態瘤都至關重要，具有很大的臨牀價值，對患者有巨大的益處。

Negotiations launched in 2017 have lowered the prices of 15 clinically-effective yet highly-priced cancer drugs such as Heceptin, Rituximab, and Bortezomib, as well as added them to the medical insurance reimbursement list.

經過協商，15種臨牀有效但價格高昂的抗癌藥物的價格在2017年進行了下調，如赫賽汀、利妥昔單抗和硼替佐米，並將這些加入到了醫療保險報銷清單。